Schering AG Launches New HRT Patch In UK

17 March 1997

Schering Health Care, the UK subsidiary of Schering AG, has launchedEthical Holding's combination estrogen/progestogen transdermal patch for use in hormone replacement therapy in the UK. According to the company this is the "first advanced-generation matrix HRT combination patch to be launched anywhere in the world."

The patch will be manufactured by Ethical Holdings, which developed the product, and will be marketed in the UK under the brand name Nuvelle by Schering, which will also market the product in other European countries once approval has been granted under the mutual recognition procedure.

Nuvelle utilizes Ethical's Jenderm drug-in-adhesive technology and is a monthly pack containing 14 days worth of estradiol-only patches, and 14 days of combination 17-beta estradiol and Schering's proprietary progestogen, levonorgestrel. It is indicated for the relief of hot flushes in peri- and post-menopausal women.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >

Today's issue

Company Spotlight

Ironwood is a US-based biotech advancing a pipeline of medicines in multiple areas of significant unmet need, including irritable bowel syndrome with constipation ((IBS-C)/chronic idiopathic constipation (CIC), vascular and fibrotic diseases, and refractory gastroesophageal reflux disease, among others.